Milnacipran for pain in fibromyalgia in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2015, Pages

  Cording, Malene ^a   Derry, Sheena ^b   Phillips, Tudor ^b   Moore, R Andrew ^b   Wiffen, Philip J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MILNACIPRAN; ANALGESIC AGENT; CYCLOPROPANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FIBROMYALGIA; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PAIN INTENSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; CHRONIC DISEASE; NEURALGIA;

ADULT; ANALGESICS; CHRONIC DISEASE; CYCLOPROPANES; FIBROMYALGIA; HUMANS; NEURALGIA; SEROTONIN UPTAKE INHIBITORS;

EID: 84964233404     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008244.pub3     Document Type: Review

References (78)

1. Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia. Arthritis and Rheumatism 2010;62(9):2745-56. [DOI: 10.1002/art.27559]2712728
2. Arnold LM, Palmer RH, Gendreau RM, Chen W. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran. Psychosomatics 2012;53(4):371-9. [DOI: 10.1016/j.psym.2012.02.005]2712729
3. Saxe PA, Arnold LM, Palmer RH, Gendreau RM, Chen W. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Current Medical Research and Opinion 2012;28(5):815-21. [DOI: 10.1185/03007995.2012.677418]2712730
4. Study of milnacipran in patients with inadequate response to duloxetine for the treatment of fibromyalgia, 2011. www.clinicaltrials.gov/ct2/show/study/NCT01077375 (accessed 22 September 2015). [CTG: NCT01077375]2712733
5. Bateman L, Palmer RH, Trugman JM, Lin Y. Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research 2013;6:311-8. [DOI: 10.2147/JPR.S43395]2712732
6. Branco JC, Cherin P, Montagne A, Bouroubi A. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. Journal of Rheumatology 2011;38(7):1403-12. [DOI: 10.3899/jrheum.101025]2712735
7. Branco JC, Zachrisson O, Perrot S, Mainguy Y. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology 2010;37(4):851-9. [DOI: 10.3899/jrheum.090884]2712736
8. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics 2008;30(11):1988-2004. [DOI: 10.1016/j.clinthera.2008.11.009]2712738
9. Clauw DJ, Mease PJ, Palmer RH, Trugman JM, Wang Y. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research and Therapy 2013;15(4):R88. [DOI: 10.1186/ar4268]2712740
10. Mease PJ, Clauw DJ, Trugman JM, Palmer RH, Wang Y. Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research 2014;7:679-87. [DOI: 10.2147/JPR.S70200]2712741
11. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. Journal of Rheumatology 2009;36(2):398-409. [DOI: 10.3899/jrheum.080734]2712743
12. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology 2005;32:1975-85. [PUBMED: 16206355]2712745
13. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology 2004;19:S27-35. [DOI: 10.1002/hup.622]2712746
14. Ang DC, Jensen MP, Steiner JL, Hilligoss J, Gracely RH, Saha C. Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial. Clinical Journal of Pain 2013;29(9):747-54. [DOI: 10.1097/AJP.0b013e31827a784e]2712748
15. Arnold LM, Palmer RH, Hufford MR, Chen W. Effect of milnacipran on body weight in patients with fibromyalgia. International Journal of General Medicine 2012;5:879-87. [DOI: 10.2147/IJGM.S36444]2712750
16. Branco JC, Cherin P, Montagne A, Bouroubi A, on behalf of the Multinational Coordinator Study Group. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. Journal of Rheumatology 2011;38(7):1403-12. [DOI: 10.3899/jrheum.101025]2712752
17. Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Medicine 2010;11(2):180-94. [DOI: 10.1111/j.1526-4637.2009.00755.x]2712754
18. Häuser W, Sarzi-Puttini P, Töle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clinical and Experimental Rheumatology 2014;30(6 (Suppl 74)):78-87. [PUBMED: 23137770]2712756
19. Kim JL, Rele S, Marks DM, Masand PS, Yerramsetty P, Millet RA, et al. Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. Primary Care Companion for CNS Disorders 2013;15(6):PCC.13m01555. [DOI: 10.4088/PCC.13m01555]2712758
20. Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y, et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician 2013;16(5):E553-62. [PUBMED: 24077206]2712760
21. Mease PJ, Palmer RH, Wang Y. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials. Journal of Clinical Rheumatology 2014;20(4):195-202. [DOI: 10.1097/RHU.0000000000000103]2712762
22. A multicenter, randomized, open-label, controlled study to evaluate the safety, tolerability, and efficacy of milnacipran when added to pregabalin in the treatment of fibromyalgia, 2011. clinicaltrials.gov/ct2/show/NCT00797797 (accessed 12 August 2011). 2712764
23. Spera A, Clauw DJ, Arnold LM, Ma Y. Long-term efficacy and tolerability of milnacipran for the management of fibromyalgia: results from an open-label, flexible-dosing study followed by a randomized, double-blind, placebo-controlled discontinuation study. Journal of General Internal Medicine. Conference: 35th Annual Meeting of the Society of General Internal Medicine, SGIM. 2012. 2712766
24. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clinical Journal of Pain 2013;29(12):1021-8. [DOI: 10.1097/AJP.0b013e31828440ab]
25. Bernstein CD, Albrecht KL, Marcus DA. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium. Expert Opinion on Pharmacotherapy 2013;14(7):905-16. [DOI: 10.1517/14656566.2013.779670]
26. Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Seminars in Arthritis and Rheumatism 2011;41(3):335-45.e6. [DOI: 10.1016/j.semarthrit.2011.06.003]
27. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304]
28. Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD011789]
29. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
30. Higgins JPT, Green S. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194-201. [DOI: 10.1016/j.pain.2009.09.017]
32. Häuser W, Petzke F, Üçeyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 2011;50(3):532-43. [DOI: 10.1093/rheumatology/keq354]
33. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010292]
34. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [DOI: org/10.1016/0197-2456(95)00134-4]
35. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339]
36. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. [DOI: 10.7326/0003-4819-135-11-200112040-00010]
37. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle TR, et al. Fibromyalgia and neuropathic pain - differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology 2011;11:55. [DOI: 10.1186/1471-2377-11-55]
38. Kyle JA, Dugan BD, Testerman KK. Milnacipran for treatment of fibromyalgia. Annals of Pharmacotherapy 2010;44(9):1422-9. [DOI: 10.1345/aph.1P218]
39. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33. [DOI: 10.7326/0003-4819-107-2-224]
40. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3]
41. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]
42. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
43. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
44. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076]
45. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain-establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]
46. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
47. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(3):260-4. [DOI: 10.1016/j.pain.2010.02.039]
48. Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 2010;149(2):173-6. [DOI: 10.1016/j.pain.2009.08.007]
49. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: 10.1016/j.pain.2010.11.030]
50. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]
51. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
52. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.00]
53. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
54. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690]
55. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94. [DOI: 10.1111/papr.12050]
56. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3]
57. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2014;18(1):67-75. [DOI: 10.1002/j.1532-2149.2013.00341.x]
58. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515]
59. Ormseth MJ, Eyler AE, Hammonds CL, Boomershine CS. Milnacipran for the management of fibromyalgia syndrome. Journal of Pain Research 2010;1(3):15-24. [DOI: 10.2147/JPR.S7883]
60. PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 11 August 2015).
61. Queiroz LP. Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports 2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5]
62. Recla JM. New and emerging therapeutic agents for the treatment of fibromyalgia: an update. Journal of Pain Research 2010;22(3):89-103. [DOI: 10.2147/JPR.S6792]
63. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
64. Roskell NS, Beard SM, Zhao Y, Le TK. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Practice 2011;11(6):516-27. [DOI: 10.1111/j.1533-2500.2010.00441.x]
65. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2]
66. Schmidt-Wilcke T, Ichesco E, Hampson JP, Kairys A, Peltier S, Harte S, et al. Resting state connectivity correlates with drug and placebo response in fibromyalgia patients. Neuroimage Clinical 2014;6:252-61. [DOI: 10.1016/j.nicl.2014.09.007]
67. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x]
68. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia - responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150]
69. Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders 2011;12:125. [DOI: 10.1186/1471-2474-12-125]
70. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29]
71. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends in the Pharmacological Sciences 2004;2512:613-7. [DOI: 10.1016/j.tips.2004.10.002]
72. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]
73. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2]
74. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33:160-72. [PUBMED: 2306288]
75. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62(5):600-10. [DOI: 10.1002/acr.20140]
76. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research 2013;645(5):777-85. [DOI: 10.1002/acr.21931]
77. Wolfe F, Walitt BT, Häuser W. What is fibromyalgia, how is it diagnosed and what does it really mean?. Arthritis Care and Research 2014;66(7):969-71. [DOI: 10.1002/acr.22207]
78. Derry S, Gill D, Phillips T, Moore RA. Milnacipran for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD008244.pub2]